Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Internal Receptors01:31

Internal Receptors

69.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.3K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

13.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
13.9K
RNA Splicing01:32

RNA Splicing

55.9K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
55.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic value of EUS-guided tissue acquisition in suspected autoimmune pancreatitis: A 15-year single-center retrospective study.

Endoscopic ultrasound·2026
Same author

Age and Education Disparities in Internalized Homophobia, Social Avoidance, Depressive Symptoms, and Sexualized Drug Use Among Men Who Have Sex with Men in China: A Mediation Analysis.

Archives of sexual behavior·2026
Same author

The safety and tolerability of oral TDF/FTC as pre-exposure prophylaxis among men who have sex with men in China: a prospective cohort study.

BMC infectious diseases·2026
Same author

Plasma Extracellular Vesicle Proteomics Reflects Graded Inflammation within the COCA Classification Framework for Chronic Pancreatitis.

Pancreas·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

Understanding SO<sub>2</sub> Reactivity with the NBD-Piperazine Motifs Commonly Used in H<sub>2</sub>S Detection and Elimination: Kinetic Insights and Tool Design.

The Journal of organic chemistry·2026

Related Experiment Video

Updated: May 31, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K

SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer.

Yuqian Yan1,2, Lei Shi3, Tao Ma4

  • 1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.

Biomolecules
|January 25, 2025
PubMed
Summary

A specific gene variant (SNP rs9364554) impacts prostate cancer drug response by altering SLC22A3 transporter levels. This finding may predict treatment outcomes and guide targeted therapies.

Keywords:
ARFOXA1SLC22A3SNP rs9364554drug efficacyprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Experiment Videos

Last Updated: May 31, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Prostate cancer treatment effectiveness is heavily influenced by androgen receptor (AR) signaling.
  • The SLC22A3 gene, a membrane transporter, is implicated in prostate cancer drug response via SNP rs9364554.
  • Understanding genetic factors affecting AR signaling is crucial for improving prostate cancer therapies.

Purpose of the Study:

  • To investigate the role of SNP rs9364554 in regulating SLC22A3 expression and its association with prostate cancer drug resistance.
  • To explore the molecular mechanisms by which this SNP influences transcription factor binding and gene regulation.
  • To identify potential biomarkers for predicting chemotherapeutic outcomes in prostate cancer.

Main Methods:

  • Genome-wide analysis of SNP rs9364554 location and its association with SLC22A3 transcription using TCGA data.
  • Validation in prostate cancer cell lines via quantitative PCR and Western blotting.
  • Electrophoretic mobility shift assay (EMSA) and ChIP-Seq to assess transcription factor binding and H3K27ac enrichment at the SLC22A3 promoter.

Main Results:

  • SNP rs9364554 is located within the SLC22A3 gene, affecting its transcription levels.
  • Downregulation of SLC22A3 correlates with increased drug resistance in prostate cancer.
  • The SNP influences the binding affinity of transcription factors FOXA1 and AR, modulating SLC22A3 regulation.

Conclusions:

  • SNP rs9364554 serves as a potential biomarker for predicting prostate cancer chemotherapeutic response.
  • The study elucidates mechanisms of drug resistance involving SLC22A3 and its regulation by FOXA1 and AR.
  • Targeting FOXA1 presents a potential strategy to enhance drug efficacy in advanced prostate cancer patients.